11TH RHEUMA ASSIUT

ANNUAL INTERNATIONAL CONFERENCE OF RHEUMATOLOGY AND REHABILITATION DEPARTMENT

IN COLLABORATION WITH EGYPTIAN SOCIETY OF RHEUMATIC DISEASES

4 DEC 2025 | ASSIUT UNIVERSITY



UNDER PATRONAGE OF

PROF. AHMED EL – MINSHAWY
President of Assuit University

PROF. ALAA ATTIA
Dean of Faculty of Medicine

PROF. ZAHRAA ABOUELEYOUN
Head of Rheumatology and Rehabilitation Department
President of the Conference

PURE SPOT EVENTS MANAGEMENT

Thursday, 4 December

8:30 - 9:30 Am — **Registration**

9:30 - 10:00 Am — **Opening Ceremony**

SESSION 1

Friendly Fire: The Therapeutic Dilemmas in Autoimmune Disease

10:15 - 11:15 Am

Chairpersons (Alphabetic): Prof. Heba Al-Shamy, Prof. Mohamed Hassan, Prof. Rania Gamal Abdel-Motaal, Prof. Samir Kamal, Prof. Tayseer M. Khedr

10:15 - 10:25 Am — **الدواء فيه سم قاتل**
Dr. Amira Anas

10:25 - 10:40 Am — **Caught in Action: Unmasking Drug Induced Connective Tissue Diseases**
Dr. Amira Mostafa Al-Sonbaty

10:40 - 10:50 Am — **Everyone is a Suspect Until Proved Otherwise !**
Dr. Al-Zahraa Awny

10:50 - 11:05 Am — **Points to Consider for Kidney Health in Rheumatology**
Prof. Nadia Kamel

11:05 - 11:15 Am — **Discussion**

Thursday, 4 December

Symposium
(Pharma overseas Import & Export)

11:15 - 11:35 Am

Chairperson: Prof. Eman Omran

20 min — **Prof. Essam Abda**

11:35 - 12:00 Pm — **COFFEE BREAK**
P R A Y E R

SESSION 2

Fever Dilemma in Rheumatic Diseases

12:00 - 1:15 Pm

Chairpersons (Alphabetic): Prof. Adela Mahmoud, Prof. Eman Al-Kady, Prof. Fatma Ali, Prof. Gihan omar, Prof. Hanan Kotb, Prof. Hanan Nafeh, Prof. Hesham Habib, Prof. Mohamed Mounir, Prof. Sabila Goma, Prof. Samar H. Goma

12:00 - 12:10 Pm — **The Other Side of Dark Night**
Dr. Reem Amr

12:10 - 12:20 Pm — **What's behind Macrophage Activation Syndrome (MAS)?**
Dr. Amira Mohammad

12:20 - 12:35 Pm — **Fever: A Specialist View**
Prof. Mohamed A. Medhat

12:35 - 12:50 Pm — **The Mystery of Fever in Rheumatology**
Prof. Sahar Fathi

12:50 - 01:05 Pm — **FUO in Child: Rheumatology Perspective**
Prof. Mervat Eissa

01:05 - 01:15 Pm — **Discussion**

Thursday, 4 December

Symposium (AstraZeneca)

1:15 - 1:35 Pm

Chairperson: Prof. Marwa Mahmoud

20 min — **Prof. Zahraa Aboueleoyoun**

SESSION 3

Advances in Neurorehabilitation

1:35 - 2:15 Pm

Chairpersons (Alphabetic): Prof. Faten Ismail, Prof. Hanan Abou-zaid, Prof. Hanaa Abou-omar, Dr. Loaay Ajlan, Prof. Mohamed Emam, Prof. Mervat Ismail, Prof. Nihal Fathi

01:35 - 01:50 Pm — **Targeted Rehabilitation Program in Spinal Cord Injury**
Prof. Ahmed El-Yasaki

01:50 - 02:05 Pm — **Advance in Geriatric Rehabilitation**
Prof. Shereen Fawaz

02:05 - 02:15 Pm — **Discussion**

Symposium (Novartis)

2:15 - 2:35 Pm

Chairperson: Prof. Gehan I. Salem

20 min — **Prof. Essam Abda**

02:35 - 03:00 Pm — **BREAK**

Thursday, 4 December

SESSION 4

Beyond the Joints: A Practical Guide to Management of Rheumatoid Arthritis/ Osteoporosis

3:00 - 4:30 Pm

Chairpersons (Alphabetic): Prof. Abeer Laz, Prof. Ali Eldeeb, Prof. Hanan Al-Saadany, Prof. Medhat Mohy Eldin, Prof. Naglaa Gadallah, Prof. Samir Al-Badawy, Prof. Zahraa Aboueleyoun

The Emerging Paradigm in Management of Rheumatoid Arthritis

Prof. Amal Al-Ganzoury

Calcium & Vitamin D: Conjoint Twins for optimum Bone Health

Prof. Osama Asheer

ABC of Osteoporosis

Prof. Zahraa Aboueleyoun

Guidelines for Diagnosis and Treatment of Osteoporosis: When to start treatment and when to stop

Prof. Samir Al-Badawy

Discussion

Symposium (Sandoz)

4:30 - 4:50 Pm

Chairperson: Prof. Manal M. Hassanein

20 min — **Prof. Essam Abda**

Thursday, 4 December

SESSION 5

The Granuloma Riddle:
Solving Diagnostic Challenges in Rheumatology

4:50 - 6:10 Pm

Chairpersons (Alphabetic): Prof. Ahmed Roshdy, Prof. Dalia Fayez, Prof. Enas Aboul-khair, Prof. Essam Abda, Prof. Essam Aboulfadl, Prof. Mohamed Ismail, Prof. Soha Senara, Prof. Yasser Ezzat

04:50 - 05:00 Pm	**The Hard Time for Factory Workers capital** Dr. Basma Zareef
05:00 - 05:10 Pm	**The Hidden Secret behind Asthma** Dr. Sylvia Vector
05:10 - 05:25 Pm	**Rheumatologic View of Granuloma capital** Prof. Essam Abda
05:25 - 05:35 Pm	**The Train that doesn't Stop at any Station** Dr. Nada Mohsen
05:35 - 05:50 Pm	**Granulomatous Mastitis** Prof. Mohamed ElWakd
05:50 - 06:00 Pm	**What's behind Macrophage Activation Syndrome (MAS) part 2** Dr. Amira Mohammad
06:00 - 06:15 Pm	**IgG4 related Diseases "The New Concept"** Prof. Samah El-Bakry
06:15 - 06:30 Pm	**Discussion**
08:30 Pm	**Gala Dinner**

Bretta Win

GEL & SPRAY

WIN THE RACE

ADVANCED FORMULA TO IMPROVE MOBILITY

10 Active Ingredients: Tocopherol (Vitamin E), Camphor Peppermint oils ,Thyme, Clove, Eucalyptus oils **Curcumin**, **Glycyrrhizin**, Betaine and Docosahexaenoic Acid.

- Anti-inflammatory
- Analgesic
- Counter-irritant
- Anasthetic
- Anti-edema



- Augmented mechanisms for effective relief
- Rapid onset (two-fold penetration power)
- Effective for both nociceptive and neuropathic pain
- The only with Curcumin/Glycyrrhizin combination
- Proven efficacy in musculoskeletal painful conditions

- Low back pain
- Arthritis
- Tendonitis
- Sprains-Strains
- Neuropathic pain
- Muscle soreness



Bretta

www.brettapharma.com

RINVOQ IN NUMBERS:

RINVOQ experience across Rheumatology, Dermatology & Gastroenterology

>7 YEARS OF PHASE 3 CLINICAL TRIAL EXPERIENCE[9]*

7 INDICATIONS

>13,500 Patients included in...

20 Phase 3 trials in the RINVOQ clinical trial program from all treatment arms[2,10†]

RINVOQ's INDICATIONS:[3,11]

- Moderate to severe active rheumatoid arthritis (RA) (RINVOQ 15&30 mg)
- Active psoriatic arthritis (PsA) (RINVOQ 15&30 mg)
- Active non-radiographic axial spondyloarthritis (nr-axSpA) (RINVOQ 15&30 mg)
- Active ankylosing spondylitis (AS) (RINVOQ 15&30 mg)
- Moderate to severe atopic dermatitis (AD) (RINVOQ 15&30 mg)
- Moderately to severely active ulcerative colitis (UC) (RINVOQ 45 mg)
- Moderately to severely active Crohn's disease (CD) (RINVOQ 45 mg)

*Beginning in RA. First patients dosed December 2015 in a RA Phase 3 clinical trial. †120,108 RA patients, 30,281 AS and PsA patients, 33,325 AD patients, and 7,002 UC patients taking RINVOQ globally. Global patient numbers include OUS+US through December 2022. Numbers are subject to change based on local market data adjustments. ‡Total patient number was calculated from adding the number of patients randomized in 20 trials. 13,557 patients includes all patients across all arms (active treatment and placebo) in the following Phase 3 trials in RA: (SELECT-EARLY, SELECT-NEXT, SELECT-COMPARE, SELECT-MONOTHERAPY, SELECT-BEYOND, SELECT-CHOICE), PsA (SELECT-PsA 1, SELECT-PsA 2), AS (SELECT-AXIS 1, SELECT-AXIS 2), PsA (SELECT-AXIS 2), AD (MEASURE UP 1, MEASURE UP 2, AD UP, HEADS UP), UC (U-ACHIEVE [UC-1], U-ACCOMPLISH [UC-2]), and CD (U-EXCEED [CD-1] and U-EXCEL [CD-2]). 7,932 patients were randomized to receive RINVOQ at any dose. Patients randomized to RINVOQ include 344 adolescent patients with moderate to severe AD not adequately controlled by topical medication(s).

EG-RNQ-250001

RINVOQ® upadacitinib

Thanks to our sponsors

NOVARTIS

SANDOZ A Novartis Division

AstraZeneca

Bretta
FOR PHARMACEUTICAL INDUSTRIES

abbvie

Roche

MINAPHARM PHARMACEUTICALS

COPAD™ PHARMA

ALESRAA PHARMACEUTICALS

HEALTH FOR LIFE
INTERNATIONAL PHARMACEUTICAL

MULTI Care
For Pharmaceutical Industries
EGYPT



PROJECT MANAGER

MRS. SARAH ESSAM

01000969356 SARAH.ESSAM@PURESPOT.ORG

HEADQUARTER: 62 MAKRAM EBEID ST., 6TH ZONE, NASR CITY, 4TH & 5TH FLOOR.

CAIRO ALEXANDRIA LUXOR DELTA ASYUT DUBAI

FOLLOW US

20 YEARS OF EXCELLENCE

PURE SPOT

www.purespot.org